Usefulness of vonoprazan,a potassium ion-competitive acid blocker,for primary eradication of Helicobacter pylori

被引:8
作者
Shinya Yamada [1 ]
Takumi Kawakami [1 ]
Yoshikazu Nakatsugawa [1 ]
Takahiro Suzuki [1 ]
Hideki Fujii [1 ]
Naoya Tomatsuri [1 ]
Hideki Nakamura [1 ]
Hideki Sato [1 ]
Yusuke Okuyama [1 ]
Hiroyuki Kimura [1 ]
Norimasa Yoshida [1 ]
机构
[1] Department of Gastroenterology,Japanese Red Cross Kyoto Daiichi Hospital
关键词
Helicobacter pylori; Eradication; Vonoprazan; Chronic gastritis; Potassium ion-competitive acid blocker;
D O I
暂无
中图分类号
R573 [胃疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To investigate usefulness of triple therapy with vonoprazan,a potassium ion-competitive acid blocker and antibiotics,for Helicobacter pylori(H.pylori) eradication.METHODS The H.pylori eradication rate was examined in 2507 patients(2055 undergoing primary eradication and 452 undergoing secondary eradication,excluding patients with subtotal gastrectomy) at the Japanese Red Cross Kyoto Daiichi Hospital from March 2013 to September 2015.For patients treated from March 2013 to February 2015,a proton pump inhibitor(PPI) was used to reduce acid secretion,while vonoprazan was used after March 2015.The success rates of the 2 regimens(PPI + amoxicillin + clarithromycin/metronidazole,or vonoprazan + amoxicillin + clarithromycin/metronidazole) were compared.RESULTS The success rate of primary H.pylori eradication was significantly higher in the vonoprazan group.When stratified by the underlying disease,a significant increase of the H.pylori eradication rate was observed in patients with chronic gastritis.A significantly lower H.pylori eradication rate was observed in younger patients compared to older patients in the PPI group,but there was no difference according to age in the vonoprazan group.On the otherhand,the success rate of secondary eradication was similar at approximately 90% in both groups.CONCLUSION Vonoprazan is very useful for primary eradication of H.pylori,and may become a first-line acid secretion inhibitor instead of PPIs.
引用
收藏
页码:550 / 555
页数:6
相关论文
共 8 条
[1]   Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study [J].
Sakurai, Y. ;
Mori, Y. ;
Okamoto, H. ;
Nishimura, A. ;
Komura, E. ;
Araki, T. ;
Shiramoto, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (06) :719-730
[2]  
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK ‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects[J] . H. Jenkins,Y. Sakurai,A. Nishimura,H. Okamoto,M. Hibberd,R. Jenkins,T. Yoneyama,K. Ashida,Y. Ogama,S. Warrington. Aliment Pharmacol Ther . 2015 (7)
[3]  
The fight against gastric cancer – the IARC Working group report[J] . Dr. Rolando Herrero,Jin Young Park. Best Practice & Research Clinical Gastroenterology . 2014
[4]   Efficacy of Tailored Helicobacter pylori Eradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion [J].
Sugimoto, Mitsushige ;
Uotani, Takahiro ;
Sahara, Shu ;
Ichikawa, Hitomi ;
Yamade, Mihoko ;
Sugimoto, Ken ;
Furuta, Takahisa .
HELICOBACTER, 2014, 19 (04) :312-318
[5]   Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population [J].
Shimoyama, T ;
Fukuda, S ;
Mikami, T ;
Fukushi, M ;
Munakata, A .
JOURNAL OF GASTROENTEROLOGY, 2004, 39 (10) :927-930
[6]  
High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection[J] . H.Isomoto,K.Inoue,H.Furusu,A.Enjoji,C.Fujimoto,M.Yamakawa,Y.Hirakata,K.Omagari,Y.Mizuta,K.Murase,S.Shimada,I.Murata,S.Kohno. Alimentary Pharmacology & Therapeutics . 2003 (1)
[7]   Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? [J].
Miwa, H ;
Nagahara, A ;
Kurosawa, A ;
Ohkusa, T ;
Ohkura, R ;
Hojo, M ;
Enomoto, N ;
Sato, N .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1545-1551
[8]  
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance[J] . K.Murakami,R.Sato,T.Okimoto,M.Nasu,T.Fujioka,M.Kodama,J.Kagawa. Alimentary Pharmacology & Therapeutics . 2002 (1)